Download Files:
CBR-470-1
SKU
HY-134205A-10 mg
Category Reference compound
Tags Keap1-Nrf2, Metabolic Disease; Neurological Disease, NF-κB
$70 – $650
Products Details
Product Description
– CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP+-induced cytotoxicity through activation of the Keap1-Nrf2 cascade[1][2].
Web ID
– HY-134205A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C14H20ClNO4S2
References
– [1]Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562(7728):600-604.|[2]Zheng J, et, al. PGK1 inhibitor CBR-470-1 protects neuronal cells from MPP+. Aging (Albany NY). 2020 Jul 10;12(13):13388-13399.
CAS Number
– 2416095-06-0
Molecular Weight
– 365.89
Compound Purity
– 98.03
SMILES
– CC(C)CN[C@H]([C@@H](S(=O)(C1=CC=C(Cl)C=C1)=O)C2)CS2(=O)=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Neurological Disease
Solubility
– DMSO : 200 mg/mL (ultrasonic)
Target
– Keap1-Nrf2
Pathway
– NF-κB
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.